
UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 192 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in UroGen Pharma
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – URGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

UroGen Pharma stock price (NASDAQ: URGN)
Use our graph to track the performance of URGN stocks over time.UroGen Pharma shares at a glance
Latest market close | $8.19 |
---|---|
52-week range | $4.85 - $19.66 |
50-day moving average | $6.55 |
200-day moving average | $10.21 |
Wall St. target price | $25.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-5.05 |
Buy UroGen Pharma shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy UroGen Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
UroGen Pharma price performance over time
Historical closes compared with the close of $8.19 from 2022-06-30
1 week (2022-06-23) | 3.80% |
---|---|
1 month (2022-06-01) | 57.80% |
3 months (2022-04-01) | -6.29% |
6 months (2021-12-31) | -13.88% |
1 year (2021-07-01) | -47.70% |
---|---|
2 years (2020-07-01) | -67.88% |
3 years (2019-07-01) | 36.44 |
5 years (2017-06-30) | 18.06 |
UroGen Pharma financials
Revenue TTM | $54.1 million |
---|---|
Gross profit TTM | $42.9 million |
Return on assets TTM | -41.87% |
Return on equity TTM | -381.3% |
Profit margin | -209.3% |
Book value | $0.38 |
Market capitalisation | $186.1 million |
TTM: trailing 12 months
UroGen Pharma share dividends
We're not expecting UroGen Pharma to pay a dividend over the next 12 months.
UroGen Pharma share price volatility
Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $4.85 up to $19.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.4188. This would suggest that UroGen Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
UroGen Pharma overview
UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer.
UroGen Pharma in the news
Do Institutions Own UroGen Pharma Ltd. (NASDAQ:URGN) Shares?
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Frequently asked questions
What percentage of UroGen Pharma is owned by insiders or institutions?Currently 8.959% of UroGen Pharma shares are held by insiders and 80.685% by institutions. How many people work for UroGen Pharma?
Latest data suggests 192 work at UroGen Pharma. When does the fiscal year end for UroGen Pharma?
UroGen Pharma's fiscal year ends in December. Where is UroGen Pharma based?
UroGen Pharma's address is: 400 Alexander Park, Princeton, NJ, United States, 08540 What is UroGen Pharma's ISIN number?
UroGen Pharma's international securities identification number is: IL0011407140 What is UroGen Pharma's CUSIP number?
UroGen Pharma's Committee on Uniform Securities Identification Procedures number is: M96088105
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert